ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma

This study is testing a new drug called ST-067 given alongside an approved immune cell therapy (liso-cel, a type of CAR-T therapy) for people with large B-cell lymphoma — an aggressive blood cancer — that has come back or is not responding to previous treatments. ST-067 aims to make the CAR-T therapy work better and last longer. **You may be eligible if...** - You are 18 or older - You have large B-cell lymphoma that has not responded to at least 2 prior treatments and qualifies for liso-cel therapy - Your tumor expresses a protein called CD19 - Your heart, lungs, kidneys, and liver are functioning adequately - Your blood counts are sufficient for the pre-treatment chemotherapy - You have a Karnofsky performance score of 60% or higher **You may NOT be eligible if...** - You have previously received any CD19 CAR-T therapy - You have active hepatitis B, hepatitis C, or HIV - You have active autoimmune disease requiring systemic treatment (some exceptions apply) - You have had a serious heart event (heart attack, severe heart failure) in the past 6 months - You are pregnant or breastfeeding - You have active brain involvement from lymphoma (some exceptions for leptomeningeal disease) - You have had a solid organ transplant Talk to your doctor to see if this trial is right for you.